Read about tumour-associated neutrophils in our October 2019 issue

Latest Reviews

  • Perspective |

    A systems biology-based approach incorporating multiscale, longitudinal measurements (from single-cell analyses to whole-body monitoring) would help to decipher the complexity of cancer and would facilitate the development of personalized therapies. The authors of this Perspective discuss how systems biology-based approaches can provide data for early detection of disease transitions, prediction of therapeutic responses and clinical outcomes, and for the design of personalized treatments.

    • James T. Yurkovich
    • , Qiang Tian
    • , Nathan D. Price
    •  & Leroy Hood
  • Review Article |

    Oncolytic viruses are beginning to enter clinical use in patients with cancer despite regulatory and practical considerations precluding the widespread use of such therapies. Here, the authors describe the potential of non-viral methods in achieving oncolytic effects and how these effects might prime the development of antitumour immune responses in patients with cancer.

    • Oliver Kepp
    • , Aurelien Marabelle
    • , Laurence Zitvogel
    •  & Guido Kroemer
  • Review Article |

    The use of epigenetic drugs (epi-drugs) as single agents according to a ‘one size fits all’ approach has generally resulted in disappointing therapeutic activity. In this Review, the mechanisms by which epi-drugs can modulate the sensitivity of cancer cells to other diverse forms of anticancer therapy are described, and completed and ongoing clinical trials relating to combination therapies incorporating epi-drugs are discussed. In addition, clinical trial designs and drug development strategies aimed at optimizing the development of such combinations are outlined.

    • Daphné Morel
    • , Daniel Jeffery
    • , Sandrine Aspeslagh
    • , Geneviève Almouzni
    •  & Sophie Postel-Vinay
  • Review Article |

    HER2-targeted therapies have dramatically improved the outcomes in women with HER2-positive breast cancer. Furthermore, genetic sequencing studies have revealed HER2 alterations in a range of other cancers, including gastric cancer, colorectal cancer and non-small-cell lung cancer. In this Review the authors describe the available data on HER2-targeted therapies beyond breast cancer.

    • Do-Youn Oh
    •  & Yung-Jue Bang
  • Review Article |

    Despite promising responses in a minority of patients with cancer, considerable scope remains to improve the efficacy of both immune-checkpoint inhibitors and epigenetic drugs, with one potential strategy involving the combination of these two types of treatment. Here, the authors describe the mechanisms underlying the synergy between immune-checkpoint inhibitors and epigenetic drugs and discuss the ongoing clinical development of such combinations.

    • Michael J. Topper
    • , Michelle Vaz
    • , Kristen A. Marrone
    • , Julie R. Brahmer
    •  & Stephen B. Baylin
  • Perspective |

    Oncology phase I trials have been traditionally referred to as ‘toxicity trials’. The distinction of clinical trials into three phases has been challenged in the past few years, leading to the current situation in which response rates are increasingly reported from phase I trials. The authors dissect the ethical dilemmas surrounding the therapeutic intent of phase I trials and provide evidence of contemporary phase I trials as a therapeutic option for patients with cancer.

    • Jacob J. Adashek
    • , Patricia M. LoRusso
    • , David S. Hong
    •  & Razelle Kurzrock

News & Comment

Naturejobs.com

Nature events Directory